Search Results

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the first quarter ended March 31, 2024 and provided a business update.

Janux Therapeutics on Monday announced positive updated clinical data for both of its clinical programs in prostate cancer advanced or metastatic solid tumors.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, announced that it has commenced an underwritten public offering of $175.0 million of shares of its common stock.

Janux Therapeutics, Inc. today announced the promotion of Dr. Tommy DiRaimondo to Chief Scientific Officer.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the third quarter ended September 30, 2023, and provided a business update.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced positive updated clinical data for both of its clinical programs.

Janux Therapeutics, Inc. today announced it will host a virtual event discussing updated clinical data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 on Monday, February 26th, 2024, at 4:30PM ET.

Janux Therapeutics, Inc. announced the pricing of an underwritten public offering of 4,440,851 shares of its common stock at a public offering price of $46.50 per share and pre-funded warrants to purchase 1,935,483 shares of common stock at a price of $46.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant.